Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of brazikumab for moderately to severely active Crohn's disease
2019-001866-14Phase 3
- Sponsor
- AstraZeneca
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brazikumab in Crohn's disease, sponsored by AstraZeneca. Primary endpoint: Adverse events.
02
Drugs
brazikumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-001866-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001866-14.